MX365591B - Formulacion de metaxalona. - Google Patents

Formulacion de metaxalona.

Info

Publication number
MX365591B
MX365591B MX2016001019A MX2016001019A MX365591B MX 365591 B MX365591 B MX 365591B MX 2016001019 A MX2016001019 A MX 2016001019A MX 2016001019 A MX2016001019 A MX 2016001019A MX 365591 B MX365591 B MX 365591B
Authority
MX
Mexico
Prior art keywords
metaxalone
dosage forms
formulation
submicron
improved bioavailability
Prior art date
Application number
MX2016001019A
Other languages
English (en)
Spanish (es)
Other versions
MX2016001019A (es
Inventor
H William Bosch
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of MX2016001019A publication Critical patent/MX2016001019A/es
Publication of MX365591B publication Critical patent/MX365591B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2016001019A 2013-07-22 2014-07-22 Formulacion de metaxalona. MX365591B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857199P 2013-07-22 2013-07-22
PCT/US2014/047701 WO2015013336A1 (en) 2013-07-22 2014-07-22 Formulation of metaxalone

Publications (2)

Publication Number Publication Date
MX2016001019A MX2016001019A (es) 2016-07-19
MX365591B true MX365591B (es) 2019-06-07

Family

ID=52393794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001019A MX365591B (es) 2013-07-22 2014-07-22 Formulacion de metaxalona.

Country Status (17)

Country Link
US (7) US20160159756A1 (2)
EP (1) EP3024440B1 (2)
JP (1) JP6453876B2 (2)
KR (1) KR20160039608A (2)
CN (1) CN105431136B (2)
AU (1) AU2014293193A1 (2)
BR (1) BR112016001395A8 (2)
CA (1) CA2918908A1 (2)
CL (1) CL2016000171A1 (2)
DK (1) DK3024440T3 (2)
IL (1) IL243447A0 (2)
MX (1) MX365591B (2)
MY (1) MY181226A (2)
RU (1) RU2684914C2 (2)
SG (2) SG10201800491RA (2)
WO (1) WO2015013336A1 (2)
ZA (1) ZA201600408B (2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20200405693A1 (en) 2019-06-25 2020-12-31 Primus Pharmaceuticals, Inc. Reduced dose metaxalone formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US7714006B1 (en) * 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US20050276844A1 (en) * 2004-03-08 2005-12-15 Spiridon Spireas Bioavailable compositions of metaxalone and processes for producing the same
US20120093928A1 (en) * 2007-08-09 2012-04-19 Ranbaxy Laboratories Limited Oral metaxalone compositions
AP3138A (en) * 2009-04-24 2015-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
MX360019B (es) 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
RU2499595C1 (ru) * 2012-07-03 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ повышения качества жизни и улучшения способностей к выполнению профессиональной деятельности у пациентов с остеоартрозом, выполняющих водительские и диспетчерско-операторские функции

Also Published As

Publication number Publication date
US20180148422A1 (en) 2018-05-31
US20190152930A1 (en) 2019-05-23
ZA201600408B (en) 2017-04-26
IL243447A0 (en) 2016-02-29
AU2014293193A1 (en) 2016-01-28
CA2918908A1 (en) 2015-01-29
US20220235017A1 (en) 2022-07-28
SG11201600264TA (en) 2016-02-26
WO2015013336A1 (en) 2015-01-29
MX2016001019A (es) 2016-07-19
SG10201800491RA (en) 2018-03-28
EP3024440A4 (en) 2017-01-25
HK1225301A1 (en) 2017-09-08
US20250084043A1 (en) 2025-03-13
CN105431136B (zh) 2020-03-24
BR112016001395A8 (pt) 2020-01-14
RU2016105763A (ru) 2017-08-29
CN105431136A (zh) 2016-03-23
RU2016105763A3 (2) 2018-06-13
JP6453876B2 (ja) 2019-01-16
JP2016527251A (ja) 2016-09-08
HK1222570A1 (zh) 2017-07-07
MY181226A (en) 2020-12-21
KR20160039608A (ko) 2016-04-11
CL2016000171A1 (es) 2016-07-01
RU2684914C2 (ru) 2019-04-16
BR112016001395A2 (pt) 2017-07-25
US20210101873A1 (en) 2021-04-08
US20160159756A1 (en) 2016-06-09
EP3024440B1 (en) 2018-11-28
EP3024440A1 (en) 2016-06-01
DK3024440T3 (en) 2019-03-11
US20240150304A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
PH12015501998B1 (en) Heterocyclic compounds and their uses
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MY172578A (en) Oral dosing of glp-1 compounds
TWD179502S (zh) 相機
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
PH12015502146A1 (en) 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
MX2017008423A (es) Formulaciones transdérmicas.
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
TWD180370S (zh) 落地式逆滲透淨水器
IN2013MU03641A (2)
IN2014CH00840A (2)
UY34829A (es) Nueva dosificación y formulación
MX363378B (es) Composiciones nanoparticuladas y formulaciones de compuestos de piperazina.
GEAP201814463A (en) Pharmaceutical composition for use in increasing the trophism of nasal mucosa
IN2014DN06617A (2)
MX2016001019A (es) Formulacion de metaxalona.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
MX2015010774A (es) Formulaciones nanoparticuladas y macroparticuladas.
IN2013CH05770A (2)
PH12015502015B1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
IN2013CH02437A (2)
AU366478S (en) Handbag
TWD178255S (zh) 齒間刷

Legal Events

Date Code Title Description
FG Grant or registration